Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour

Trial Profile

Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Intestinal cancer; Neuroendocrine carcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Acronyms CLARINET
  • Sponsors Ipsen
  • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 06 Jun 2017 Results of final progression free survival analyses for subgroups (according to tumor origin and prior therapy), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 01 Jun 2017 According to an Ipsen media release, final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors will be presented at the American Society of Clinical Oncology (ASCO) 2017 conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top